146 related articles for article (PubMed ID: 37818869)
1. Selinexor for the treatment of recurrent or metastatic salivary gland tumors: Results from the GEMS-001 clinical trial.
Hernando-Calvo A; Malone E; Day D; Prawira A; Weinreb I; Yang SYC; Wong H; Rodriguez A; Jennings S; Eliason A; Wang L; Spreafico A; Siu LL; Hansen AR
Cancer Med; 2023 Oct; 12(20):20299-20310. PubMed ID: 37818869
[TBL] [Abstract][Full Text] [Related]
2. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
Thein KZ; Piha-Paul SA; Tsimberidou A; Karp DD; Janku F; Zarifa A; Shah J; Milton DR; Bean S; McQuinn L; Gong J; Colen R; Carter BW; Subbiah V; Ogbonna DC; Pant S; Meric-Bernstam F; Naing A
Invest New Drugs; 2021 Oct; 39(5):1357-1365. PubMed ID: 33909232
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).
Kim Y; Lee SJ; Lee JY; Lee SH; Sun JM; Park K; An HJ; Cho JY; Kang EJ; Lee HY; Kim J; Keam B; Kim HR; Lee KE; Choi MY; Lee KH; Ahn MJ
Cancer; 2017 Jun; 123(11):1958-1964. PubMed ID: 28102887
[TBL] [Abstract][Full Text] [Related]
4. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
Kalakonda N; Maerevoet M; Cavallo F; Follows G; Goy A; Vermaat JSP; Casasnovas O; Hamad N; Zijlstra JM; Bakhshi S; Bouabdallah R; Choquet S; Gurion R; Hill B; Jaeger U; Sancho JM; Schuster M; Thieblemont C; De la Cruz F; Egyed M; Mishra S; Offner F; Vassilakopoulos TP; Warzocha K; McCarthy D; Ma X; Corona K; Saint-Martin JR; Chang H; Landesman Y; Joshi A; Wang H; Shah J; Shacham S; Kauffman M; Van Den Neste E; Canales MA
Lancet Haematol; 2020 Jul; 7(7):e511-e522. PubMed ID: 32589977
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies.
Vergote IB; Lund B; Peen U; Umajuridze Z; Mau-Sorensen M; Kranich A; Van Nieuwenhuysen E; Haslund C; Nottrup T; Han SN; Concin N; Unger TJ; Chai Y; Au N; Rashal T; Joshi A; Crochiere M; Landesman Y; Shah J; Shacham S; Kauffman M; Mirza MR
Gynecol Oncol; 2020 Feb; 156(2):308-314. PubMed ID: 31822399
[TBL] [Abstract][Full Text] [Related]
6. A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer.
Rodriguez CP; Wu QV; Voutsinas J; Fromm JR; Jiang X; Pillarisetty VG; Lee SM; Santana-Davila R; Goulart B; Baik CS; Chow LQM; Eaton K; Martins R
Clin Cancer Res; 2020 Feb; 26(4):837-845. PubMed ID: 31796519
[TBL] [Abstract][Full Text] [Related]
7. A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma.
Lassman AB; Wen PY; van den Bent MJ; Plotkin SR; Walenkamp AME; Green AL; Li K; Walker CJ; Chang H; Tamir S; Henegar L; Shen Y; Alvarez MJ; Califano A; Landesman Y; Kauffman MG; Shacham S; Mau-Sørensen M
Clin Cancer Res; 2022 Feb; 28(3):452-460. PubMed ID: 34728525
[TBL] [Abstract][Full Text] [Related]
8. A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer.
Wei XX; Siegel AP; Aggarwal R; Lin AM; Friedlander TW; Fong L; Kim W; Louttit M; Chang E; Zhang L; Ryan CJ
Oncologist; 2018 Jun; 23(6):656-e64. PubMed ID: 29487219
[TBL] [Abstract][Full Text] [Related]
9. Salivary gland epithelial neoplasms in pediatric population: a single-institute experience with a focus on the histologic spectrum and clinical outcome.
Xu B; Aneja A; Ghossein R; Katabi N
Hum Pathol; 2017 Sep; 67():37-44. PubMed ID: 28739497
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Locati LD; Perrone F; Cortelazzi B; Bergamini C; Bossi P; Civelli E; Morosi C; Lo Vullo S; Imbimbo M; Quattrone P; Dagrada GP; Granata R; Resteghini C; Mirabile A; Alfieri S; Orlandi E; Mariani L; Saibene G; Pilotti S; Licitra L
Eur J Cancer; 2016 Dec; 69():158-165. PubMed ID: 27821319
[TBL] [Abstract][Full Text] [Related]
11. TRPS1 immunohistochemical expression in salivary gland tumors: A pilot study.
Tjendra Y; Kerr DA; Gomez-Fernandez C; Velez Torres JM
Am J Clin Pathol; 2023 Dec; 160(6):633-639. PubMed ID: 37565763
[TBL] [Abstract][Full Text] [Related]
12. Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL.
Nilsson S; Stein A; Rolfo C; Kranich AL; Mann J; Papadimitriou K; Theile S; Amberg S; Bokemeyer C
Curr Cancer Drug Targets; 2020; 20(10):811-817. PubMed ID: 32598257
[TBL] [Abstract][Full Text] [Related]
13. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.
Westin SN; Fu S; Tsimberidou A; Piha-Paul S; Akhmedzhanov F; Yilmaz B; McQuinn L; Brink AL; Gong J; Leung CH; Lin H; Hong DS; Pant S; Carter B; Jazaeri A; Gershenson D; Sood AK; Coleman RL; Shah J; Meric-Bernstam F; Naing A
Gynecol Oncol; 2023 Jan; 168():76-82. PubMed ID: 36423446
[TBL] [Abstract][Full Text] [Related]
14. A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer.
Kim HR; Lee SJ; Park S; Jung HA; Lee SH; Jeong HS; Chung MK; Ahn MJ
Cancer Res Treat; 2022 Jul; 54(3):719-727. PubMed ID: 34727492
[TBL] [Abstract][Full Text] [Related]
15. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.
Gounder MM; Razak AA; Somaiah N; Chawla S; Martin-Broto J; Grignani G; Schuetze SM; Vincenzi B; Wagner AJ; Chmielowski B; Jones RL; Riedel RF; Stacchiotti S; Loggers ET; Ganjoo KN; Le Cesne A; Italiano A; Garcia Del Muro X; Burgess M; Piperno-Neumann S; Ryan C; Mulcahy MF; Forscher C; Penel N; Okuno S; Elias A; Hartner L; Philip T; Alcindor T; Kasper B; Reichardt P; Lapeire L; Blay JY; Chevreau C; Valverde Morales CM; Schwartz GK; Chen JL; Deshpande H; Davis EJ; Nicholas G; Gröschel S; Hatcher H; Duffaud F; Herráez AC; Beveridge RD; Badalamenti G; Eriksson M; Meyer C; von Mehren M; Van Tine BA; Götze K; Mazzeo F; Yakobson A; Zick A; Lee A; Gonzalez AE; Napolitano A; Dickson MA; Michel D; Meng C; Li L; Liu J; Ben-Shahar O; Van Domelen DR; Walker CJ; Chang H; Landesman Y; Shah JJ; Shacham S; Kauffman MG; Attia S
J Clin Oncol; 2022 Aug; 40(22):2479-2490. PubMed ID: 35394800
[TBL] [Abstract][Full Text] [Related]
16. Characterisation of DOG-1 Expression in Salivary Gland Tumours and Comparison with Myoepithelial Markers.
Khurram SA; Speight PM
Head Neck Pathol; 2019 Jun; 13(2):140-148. PubMed ID: 29671211
[TBL] [Abstract][Full Text] [Related]
17. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
Chari A; Vogl DT; Gavriatopoulou M; Nooka AK; Yee AJ; Huff CA; Moreau P; Dingli D; Cole C; Lonial S; Dimopoulos M; Stewart AK; Richter J; Vij R; Tuchman S; Raab MS; Weisel KC; Delforge M; Cornell RF; Kaminetzky D; Hoffman JE; Costa LJ; Parker TL; Levy M; Schreder M; Meuleman N; Frenzel L; Mohty M; Choquet S; Schiller G; Comenzo RL; Engelhardt M; Illmer T; Vlummens P; Doyen C; Facon T; Karlin L; Perrot A; Podar K; Kauffman MG; Shacham S; Li L; Tang S; Picklesimer C; Saint-Martin JR; Crochiere M; Chang H; Parekh S; Landesman Y; Shah J; Richardson PG; Jagannath S
N Engl J Med; 2019 Aug; 381(8):727-738. PubMed ID: 31433920
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.
Wong SJ; Karrison T; Hayes DN; Kies MS; Cullen KJ; Tanvetyanon T; Argiris A; Takebe N; Lim D; Saba NF; Worden FP; Gilbert J; Lenz HJ; Razak AR; Roberts JD; Vokes EE; Cohen EE
Ann Oncol; 2016 Feb; 27(2):318-23. PubMed ID: 26598548
[TBL] [Abstract][Full Text] [Related]
19. Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.
Thein KZ; Karp DD; Tsimberidou A; Gong J; Sulovic S; Shah J; Milton DR; Hong DS; Janku F; McQuinn L; Stephen BA; Colen R; Carter BW; Yap TA; Piha-Paul SA; Fu S; Meric-Bernstam F; Naing A
Invest New Drugs; 2022 Apr; 40(2):290-299. PubMed ID: 34562230
[TBL] [Abstract][Full Text] [Related]
20. Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life.
Locati LD; Galbiati D; Calareso G; Alfieri S; Singer S; Cavalieri S; Bergamini C; Bossi P; Orlandi E; Resteghini C; Platini F; Granata R; Quattrone P; Mancinelli M; Mariani L; Lo Vullo S; Licitra LF
Cancer; 2020 Jan; 126(9):1888-1894. PubMed ID: 32031693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]